On Comparative Effectiveness: IOM Lists Priorities, VCs Expect Answers
In the US, the debate continues over comparative effectiveness research as the influential Institute of Medicine this week issued its recommendations.
More » |
|
|
Medical Science Liaisons Allowed to Discuss Off-Label Use
While drugmakers’ sales staff are prohibited by FDA from discussing unapproved uses of their companies’ products, medical science liaisons have more latitude.
More » |
More Health & Regulatory News »